A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer

A Non Interventional Trial of Tarceva Metastatic Non Small Lung Cancer.

This is a non-interventional, open label, single arm, multicenter study to assess the safety and efficacy of erlotinib in participants with non-small cell lung cancer.

Inclusion Criteria:

• It is the physician's decision to prescribe erlotinib in participants and to document their treatment
• Participants must be candidates for receiving erlotinib for locally advanced or metastatic non-small cell lung cancer according to the product label

Exclusion Criteria:

• Participants will be excluded if safety concerns occurred
• If the participant was not compliant or if the participant would wish to stop erlotinib therapy